DK1786430T3 - Små molekyler, der erstatter eller forstyrrer en p53-funktion - Google Patents

Små molekyler, der erstatter eller forstyrrer en p53-funktion

Info

Publication number
DK1786430T3
DK1786430T3 DK05786671.7T DK05786671T DK1786430T3 DK 1786430 T3 DK1786430 T3 DK 1786430T3 DK 05786671 T DK05786671 T DK 05786671T DK 1786430 T3 DK1786430 T3 DK 1786430T3
Authority
DK
Denmark
Prior art keywords
disturbing
function
small molecules
replacing
molecules replacing
Prior art date
Application number
DK05786671.7T
Other languages
English (en)
Inventor
Kayvan Niazi
Dale E Bredesen
Shahrooz Rabizadeh
Original Assignee
Buck Inst For Age Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buck Inst For Age Res filed Critical Buck Inst For Age Res
Application granted granted Critical
Publication of DK1786430T3 publication Critical patent/DK1786430T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK05786671.7T 2004-08-20 2005-08-12 Små molekyler, der erstatter eller forstyrrer en p53-funktion DK1786430T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60330804P 2004-08-20 2004-08-20
PCT/US2005/028857 WO2006023410A2 (en) 2004-08-20 2005-08-12 Small molecules that replace or agonize p53 function

Publications (1)

Publication Number Publication Date
DK1786430T3 true DK1786430T3 (da) 2013-04-22

Family

ID=35968080

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05786671.7T DK1786430T3 (da) 2004-08-20 2005-08-12 Små molekyler, der erstatter eller forstyrrer en p53-funktion

Country Status (11)

Country Link
US (2) US7994184B2 (da)
EP (2) EP1786430B1 (da)
KR (1) KR101400505B1 (da)
CN (1) CN101432001A (da)
AU (1) AU2005277648B2 (da)
CA (2) CA2580719C (da)
DK (1) DK1786430T3 (da)
ES (1) ES2406605T3 (da)
PL (1) PL1786430T3 (da)
PT (1) PT1786430E (da)
WO (1) WO2006023410A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2406605T3 (es) 2004-08-20 2013-06-07 Buck Institute For Age Research Moléculas pequeñas que sustituyen o agonizan la función p53
SG11201608303QA (en) * 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
CN108024987A (zh) * 2014-10-10 2018-05-11 德玛医药 用于治疗癌症的二去水卫矛醇的类似物或衍生物与含铂抗肿瘤药物的组合
WO2017040738A1 (en) * 2015-09-02 2017-03-09 Regeneron Pharmaceuticals, Inc. Rodent model of prostate cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1998583A (en) * 1930-01-27 1935-04-23 Ig Farbenindustrie Ag Inorganic acid esters of the condensation products of a glycol and chlorinated paraffin hydrocarbons
GB8400665D0 (en) * 1984-01-11 1984-02-15 Secr Defence Disubstituted ethanes
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4699789A (en) * 1985-09-27 1987-10-13 Eastern Artificial Insemination Cooperative, Inc. Viral free semen and methods of producing the same
AU598305B2 (en) * 1986-10-14 1990-06-21 Gekkeikan Sake Company, Ltd. Quality improvement of alcoholic liquors
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
JPH06256113A (ja) * 1993-03-01 1994-09-13 Mitsubishi Petrochem Co Ltd 除草剤組成物
US5519134A (en) * 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5659024A (en) 1994-01-14 1997-08-19 The Burnham Institute Promotors that regulate the expression of genes involved in cell death
US5593853A (en) * 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) * 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) * 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5856362A (en) * 1994-09-02 1999-01-05 Glaxo Wellcome Inc. Medicaments for the treatment of toxoplasmosis
EP0873363B1 (en) 1995-06-14 2010-10-06 The Regents of The University of California High affinity human antibodies to tumor antigens
US5569588A (en) * 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5744310A (en) * 1996-07-29 1998-04-28 The Burnham Institute Bax promoter sequence and screening assays for indentifying agents that regulate bax gene expression
US5837838A (en) * 1997-03-14 1998-11-17 The Burnham Institute Bax inhibitor proteins
US6228850B1 (en) * 1997-09-30 2001-05-08 Dabur Research Foundation Antiangiogenic activity of betulinic acid and its derivatives
US6235714B1 (en) 1998-03-23 2001-05-22 Sudhir Paul Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
KR100311949B1 (ko) * 1999-03-10 2001-11-02 최승주 1-[(사이클로펜트-3-엔-1-일)메틸]-5-에틸-6-(3,5-다이메틸벤조일)-2,4-피리미딘다이온의제조방법
DE60015568D1 (de) * 1999-08-13 2004-12-09 Univ Maryland Biotech Inst Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür
JP3507483B1 (ja) * 2000-07-21 2004-03-15 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト ４，６−ジメトキシ−２−（メチルスルホニル）−１，３−ピリミジンの製造方法
ES2406605T3 (es) 2004-08-20 2013-06-07 Buck Institute For Age Research Moléculas pequeñas que sustituyen o agonizan la función p53

Also Published As

Publication number Publication date
CA2580719A1 (en) 2006-03-02
US20060094738A1 (en) 2006-05-04
US9789121B2 (en) 2017-10-17
EP2633858A3 (en) 2013-12-11
CA2829654C (en) 2017-10-31
EP1786430A2 (en) 2007-05-23
CA2829654A1 (en) 2006-03-02
KR101400505B1 (ko) 2014-05-28
KR20070083572A (ko) 2007-08-24
AU2005277648B2 (en) 2011-12-22
EP1786430B1 (en) 2013-04-03
WO2006023410A3 (en) 2009-04-16
PT1786430E (pt) 2013-06-04
HK1104237A1 (en) 2008-01-11
PL1786430T3 (pl) 2013-09-30
EP1786430A4 (en) 2009-11-11
CA2580719C (en) 2013-10-22
WO2006023410A2 (en) 2006-03-02
AU2005277648A1 (en) 2006-03-02
US7994184B2 (en) 2011-08-09
EP2633858A2 (en) 2013-09-04
ES2406605T3 (es) 2013-06-07
CN101432001A (zh) 2009-05-13
US20120040457A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
NO2019029I1 (no) Guselkumab, se følgebrevet for nærmere forklaring
NL1031170A1 (nl) Bevestigingselement.
ATE540027T1 (de) Tetrahydroindazol-cannabinoidmodulatoren
DK1838736T3 (da) Cripto-bindende molekyler
NO20051199L (no) Rorhandteringsutstyr.
DE602006005030D1 (de) Phasenaustauschtinten
DE602005007121D1 (de) Phasenaustauschtinten
FR2893991B1 (fr) Circulateur a membrane
DK1937072T3 (da) Pesticidblandinger, der omfatter en phenylsemicarbazon
DE602006008715D1 (de) Papierspleissvorrichtung
NO20053362D0 (no) Syklofuge.
DK1864803T3 (da) Trykkemaskine
DK1786430T3 (da) Små molekyler, der erstatter eller forstyrrer en p53-funktion
DE502006005102D1 (de) Vernetzbare massen auf der basis von organosiliciumverbindungen
FI20045113A0 (fi) Tapettipaperi
NL2000351A1 (nl) Estrogeen-modulatoren.
DE602005016988D1 (de) Phasenaustauschtinte
DE502006005209D1 (de) Fungizide mischungen auf der basis von triazolen
NO20052107D0 (no) Rep.
DK1864804T3 (da) Trykkemaskine
DE602006004424D1 (de) Phasenwechseltinten
NL1029655A1 (nl) Rotor.
ES1061864Y (es) Estructura soporte publicitaria.
ITPA20050005A1 (it) Rasoio a vibrazione.
ES1059885Y (es) Sabana encimera estampada.